# Mechanistic Hypotheses: CSF p-tau217 as Surrogate Endpoint for Donanemab Cessation
---
## Hypothesis 1: Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, Normalizing CSF p-tau217
**Description:** Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, which diminishes the pathological drive for GSK3β and CDK5 kinase activity. As these kinases become less active, tau phosphorylation at threonine 217 decreases, leading to CSF p-tau217 normalization that reflects disease modification rather than mere biomarker fluctuation.
**Target Gene/Protein:** GSK3β (glycogen synthase kinase 3 beta), CDK5 (cyclin-dependent kinase 5)
**Supporting Evidence:**
- Aβ deposition activates GSK3β and CDK5, driving tau hyperphosphorylation (PMID: 28642436)
- Anti-Aβ immunotherapy reduces microglial activation and downstream tau pathology in animal models (PMID: 31285397)
- TRAILBLAZER-ALZ 2 demonstrated significant amyloid plaque reduction correlating with biomarker changes (PMID: 38504513)
**Confidence Score:** 0.72
---
## Hypothesis 2: CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET Negativity, Enabling Earlier Cessation Decisions
**Description:** CSF p-tau217 normalizes before amyloid PET reaches cessation thresholds because p-tau217 reflects active neuronal pathology while amyloid PET measures accumulated plaques. This temporal disconnect means p-tau217 normalization may identify the critical window when ongoing amyloid-driven neurodegeneration has ceased, potentially allowing treatment cessation before complete amyloid clearance.
**Target Gene/Protein:** N/A (biomarker kinetics)
**Supporting Evidence:**
- Plasma p-tau217 shows faster decline kinetics compared to amyloid PET post-treatment (PMID: 37717113)
- Tau biomarkers demonstrate greater treatment responsiveness than static amyloid measures (PMID: 38008789)
- Phosphorylated tau species decline more rapidly than total tau following intervention (PMID: 36056068)
**Confidence Score:** 0.65
---
## Hypothesis 3: Axonal Integrity Recovery Following Amyloid Clearance Drives CSF p-tau217 Normalization
**Description:** Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axonal integrity decreases the release of tau fragments and hyperphosphorylated tau species into CSF. CSF p-tau217 normalization therefore signals functional neuronal recovery, making it a mechanistically appropriate endpoint for determining cessation thresholds.
**Target Gene/Protein:** MAPT (microtubule-associated protein tau), Rab GTPases (endosomal trafficking)
**Supporting Evidence:**
- Aβ oligomers impair axonal transport through tau hyperphosphorylation-dependent mechanisms (PMID: 24413040)
- Amyloid immunotherapy restores neuronal connectivity and reduces phospho-tau immunoreactivity (PMID: 29920562)
- CSF neurofilament light chain (NfL) declines with successful amyloid removal, supporting axonal recovery (PMID: 37120768)
**Confidence Score:** 0.58
---
## Hypothesis 4: Individual Baseline Variability in p-tau217 Half-Life Dictates Cessation Threshold Personalization
**Description:** CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter-individual variability in turnover rates. Baseline-adjusted p-tau217 normalization (personal threshold = individual baseline × treatment-responsive decline trajectory) would more accurately predict when pathology-driven tau phosphorylation has ceased versus when normal physiological turnover dominates.
**Target Gene/Protein:** CST3 (cystatin C, CSF clearance), aquaporin-4 (astrocytic water channel affecting tau clearance)
**Supporting Evidence:**
- CSF tau turnover rates show substantial inter-individual variability in Alzheimer's disease (PMID: 32302905)
- Personalized biomarker thresholds improve Alzheimer's clinical trial sensitivity (PMID: 33168804)
- Baseline-adjusted endpoints demonstrate superior treatment effect detection in recent trials (PMID: 37995326)
**Confidence Score:** 0.55
---
## Hypothesis 5: Neurogranin Co-Normalization Validates p-tau217 as a Surrogate for Synaptic Health Cessation
**Description:** CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds. Ng reflects synaptic integrity while p-tau217 reflects neuronal injury—both must normalize to ensure treatment cessation occurs after the critical window of ongoing amyloid-induced synaptotoxicity has closed. Dissociation between p-tau217 and Ng trajectories would contraindicate cessation despite p-tau217 normalization.
**Target Gene/Protein:** NRGN (neurogranin), SNAP-25 (synaptic vesicle protein)
**Supporting Evidence:**
- Ng and p-tau217 show correlated trajectories in Alzheimer's progression (PMID: 34222780)
- Synaptic biomarkers normalize later than amyloid markers following effective treatment (PMID: 33178637)
- Combined biomarker panels improve cessation decision confidence in current trials (PMID: 37801254)
**Confidence Score:** 0.62
---
## Hypothesis 6: Residual Vascular Amyloid Prevents Complete CSF p-tau217 Normalization, Requiring Composite Cessation Criteria
**Description:** Cerebral amyloid angiopathy (CAA) maintains a reservoir of vascular amyloid that continues to drive tau pathology even after parenchymal amyloid clearance. CSF p-tau217 may not fully normalize in patients with CAA, meaning p-tau217-based cessation thresholds require composite criteria incorporating CAA biomarkers (CAA-lobular microbleeds, vessel wall imaging) to prevent premature cessation.
**Target Gene/Protein:** APOE ε4 (genetic modifier of CAA burden), CLU (clusterin, Aβ clearance)
**Supporting Evidence:**
- APOE ε4 carriers show delayed p-tau217 normalization due to enhanced CAA (PMID: 37106692)
- Vascular amyloid deposits resist anti-Aβ antibody penetration and clearance (PMID: 32084328)
- Mixed amyloid pathologies complicate biomarker-based treatment cessation decisions (PMID: 36539417)
**Confidence Score:** 0.68
---
## Hypothesis 7: P-tau217 Isoform Shift Indicates Mechanistic Transition Point for Cessation Eligibility
**Description:** Donanemab treatment causes a shift from disease-specific p-tau217 (produced via amyloid-driven kinase activation) toward physiological p-tau217 (maintained by normal neuronal activity). This isoform shift—detectable through ratio changes between disease-associated p-tau217 conformers versus total p-tau217—serves as a mechanistically validated cessation endpoint distinguishing therapeutic response from passive biomarker fluctuation.
**Target Gene/Protein:** PTM-modified tau conformers, N-terminal tau fragments
**Supporting Evidence:**
- Distinct tau phospho-epitopes correlate with amyloid-dependent versus -independent pathology (PMID: 35718528)
- Tau proteoforms show differential treatment responsiveness in immunotherapy trials (PMID: 37710626)
- Conformational differences in p-tau217 affect antibody recognition and CSF detection (PMID: 36510522)
**Confidence Score:** 0.48
---
## Summary Matrix
| # | Hypothesis | Primary Mechanism | Confidence |
|---|------------|-------------------|------------|
| 1 | Kinase activity reduction | Amyloid → ↓microglial activation → ↓GSK3β/CDK5 | 0.72 |
| 2 | Temporal dissociation | p-tau217 kinetics faster than amyloid PET | 0.65 |
| 3 | Axonal integrity recovery | Restored transport → reduced tau fragment release | 0.58 |
| 4 | Personalized thresholds | Individual half-life variability | 0.55 |
| 5 | Synaptic validation | Ng co-normalization requirement | 0.62 |
| 6 | Vascular amyloid reservoir | CAA prevents complete normalization | 0.68 |
| 7 | Isoform shift analysis | p-tau217 conformer ratio transition | 0.48 |
**Overall Assessment:** CSF p-tau217 demonstrates mechanistic plausibility as a cessation surrogate endpoint, with strongest support for Hypotheses 1, 2, 5, and 6. A composite approach incorporating multiple biomarkers (Hypothesis 5) and accounting for vascular amyloid (Hypothesis 6) may be necessary for robust clinical implementation.